Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $45.38 Average Price Target from Brokerages

Pliant Therapeutics, Inc. (NASDAQ:PLRX) has earned a consensus rating of “Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $45.38.

Several research firms recently issued reports on PLRX. Oppenheimer lifted their price objective on Pliant Therapeutics from $47.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Pliant Therapeutics in a report on Friday. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a report on Tuesday, May 7th. Royal Bank of Canada dropped their price target on Pliant Therapeutics from $54.00 to $45.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. Finally, Citigroup dropped their price target on Pliant Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th.

Pliant Therapeutics Stock Up 3.2 %

NASDAQ:PLRX opened at $11.51 on Thursday. Pliant Therapeutics has a 52 week low of $10.60 and a 52 week high of $24.74. The company has a debt-to-equity ratio of 0.07, a quick ratio of 16.12 and a current ratio of 16.12. The stock’s 50-day moving average price is $13.31 and its 200-day moving average price is $15.25.

Pliant Therapeutics (NASDAQ:PLRX) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.02). Sell-side analysts predict that Pliant Therapeutics will post -3.44 EPS for the current year.

Institutional Trading of Pliant Therapeutics

Several hedge funds have recently modified their holdings of the stock. Quest Partners LLC purchased a new position in Pliant Therapeutics in the fourth quarter valued at $37,000. China Universal Asset Management Co. Ltd. increased its holdings in Pliant Therapeutics by 353.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,929 shares of the company’s stock valued at $125,000 after buying an additional 5,400 shares during the last quarter. SG Americas Securities LLC purchased a new position in Pliant Therapeutics in the first quarter valued at $107,000. Corton Capital Inc. purchased a new position in Pliant Therapeutics in the third quarter valued at $197,000. Finally, Rathbones Group PLC purchased a new position in Pliant Therapeutics in the third quarter valued at $203,000. 97.30% of the stock is currently owned by institutional investors and hedge funds.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.